Correction to Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial (The Lancet Diabetes & Endocrinology (2019) 7(5) (356–367), (S221385871930066X), (10.1016/S2213-8587(19)30066-X));Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

The Lancet Diabetes and Endocrinology

Volumn 7, Issue 5, 2019, Pages 356-367

  Zinman, Bernard ^a   Bhosekar, Vaishali ^b   Busch, Robert ^c   Holst, Ingrid ^d   Ludvik, Bernhard ^e   Thielke, Desirée ^d   Thrasher, James ^f   Woo, Vincent ^g   Philis Tsimikas, Athena ^h  

^a MOUNT SINAI HOSPITAL   (Canada)

^b Raheja Towers   (India)

^c ALBANY MEDICAL CENTER   (United States)

^d NOVO NORDISK A S   (Denmark)

^e KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^f Medical Investigations Inc   (United States)

^g UNIVERSITY OF MANITOBA   (Canada)

^h Whittier Institute for Diabetes   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; ARTICLE; AUSTRIA; BODY WEIGHT CHANGE; CANADA; CARDIOVASCULAR DISEASE; CONSTIPATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPOVOLEMIA; JAPAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NORWAY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION; SIDE EFFECT; UNITED STATES; URINARY TRACT INFECTION; VOMITING; ADMINISTRATION AND DOSAGE; ADVERSE EVENT; AGED; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLACEBOS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85062195534     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(19)30323-7     Document Type: Erratum

References (29)

1. Davies, MJ, D'Alessio, DA, Fradkin, J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41 (2018), 2669–2701.
2. No authors listedIntroduction: standards of medical care in diabetes—2019. Diabetes Care 42:suppl 1 (2019), S1–S2.
3. Marso, SP, Bain, SC, Consoli, A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
4. Zinman, B, Wanner, C, Lachin, JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
5. Neal, B, Perkovic, V, Mahaffey, KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
6. Marso, SP, Daniels, GH, Brown-Frandsen, K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
7. Wiviott, SD, Raz, I, Bonaca, MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 (2019), 347–357.
8. Hernandez, AF, Green, JB, Janmohamed, S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392 (2018), 1519–1529.
9. Novo Nordisk. Ozempic (semaglutide). Summary of product characteristics. www.ema.europa.eu/documents/product-information/ozempic-epar-product-information_en.pdf. (Accessed 21 February 2019)
10. Novo Nordisk. Ozempic (semaglutide). Prescribing information. www.novo-pi.com/ozempic.pdf, December, 2017. (Accessed 21 February 2019)
11. Sorli, C, Harashima, SI, Tsoukas, GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 5 (2017), 251–260.
12. Rodbard, HW, Lingvay, I, Reed, J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab 103 (2018), 2291–2301.
13. Ahrén, B, Masmiquel, L, Kumar, H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol 5 (2017), 341–354.
14. Ahmann, AJ, Capehorn, M, Charpentier, G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care 41 (2018), 258–266.
15. Aroda, VR, Bain, SC, Cariou, B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol 5 (2017), 355–366.
16. Pratley, RE, Aroda, VR, Lingvay, I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 6 (2018), 275–286.
17. Ludvik, B, Frias, JP, Tinahones, FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 6 (2018), 370–381.
18. Frias, JP, Guja, C, Hardy, E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4 (2016), 1004–1016.
19. International Conference on HarmonisationICH harmonised tripartite guideline: Guideline for Good Clinical Practice E6(R1). www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf, June 10, 1996. (Accessed 21 February 2019)
20. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310 (2013), 2191–2194.
21. American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes—2018. Diabetes Care 41 (2018), S55–S64.
22. Handelsman, Y, Bloomgarden, ZT, Grunberger, G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. Endocr Pract 21 (2015), 1–87.
23. Seaquist, ER, Anderson, J, Childs, B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36 (2013), 1384–1395.
24. Patel, V, Joharapurkar, A, Shah, G, Jain, M, Effect of GLP-1 based therapies on diabetic dyslipidemia 10 (2014), 238–250.
25. Goud, A, Zhong, J, Peters, M, Brook, R, Rajagopalan, S, GLP-1 agonists and blood pressure: a review of the evidence. Curr Hypertens Rep, 18, 2018, 16.
26. Meloni, AR, DeYoung, MB, Lowe, C, Parkes, DG, GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab 15 (2013), 15–27.
27. Kalra, S, Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther 5 (2014), 355–366.
28. Lee, PC, Ganguly, S, Goh, SY, Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev 19 (2018), 1630–1641.
29. Handelsman, Y, Wyne, K, Cannon, A, Shannon, M, Schneider, D, Glycemic efficacy, weight effects, and safety of once-weekly glucagon-like peptide-1 receptor agonists. J Manag Care Spec Pharm 24 (2018), S14–S29.